Opinion: Novartis' generics move shows U.S. policy discourages innovation

03/16/2005 | Forbes

The move by European drugmaker Novartis to buy two generic drug companies is a result of U.S. government policies that "place short-term savings ahead of long-term research and development," writes Dr. Scott Gottlieb, editor of Forbes/Gottlieb Medical Technology Investor. If Novartis had entered the generics market 10 years earlier, leukemia patients would be without its breakthrough Gleevec drug today, he says.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX